National Center for Child and Adolescent Health, Ministry of Health, Mexico City.
N Engl J Med. 2010 Jan 28;362(4):299-305. doi: 10.1056/NEJMoa0905211.
A phased introduction of a monovalent rotavirus vaccine occurred in Mexico from February 2006 through May 2007. We assessed the effect of vaccination on deaths from diarrhea in Mexican children in 2008 and 2009.
We obtained data on deaths from diarrhea, regardless of cause, from January 2003 through May 2009 in Mexican children under 5 years of age. We compared diarrhea-related mortality in 2008 and during the 2008 and 2009 rotavirus seasons with the mortality at baseline (2003-2006), before the introduction of the rotavirus vaccine. Vaccine coverage was estimated from administrative data.
By December 2007, an estimated 74% of children who were 11 months of age or younger had received one dose of rotavirus vaccine. In 2008, there were 1118 diarrhea-related deaths among children younger than 5 years of age, a reduction of 675 from the annual median of 1793 deaths during the 2003-2006 period. Diarrhea-related mortality fell from an annual median of 18.1 deaths per 100,000 children at baseline to 11.8 per 100,000 children in 2008 (rate reduction, 35%; 95% confidence interval [CI], 29 to 39; P<0.001). Among infants who were 11 months of age or younger, diarrhea-related mortality fell from 61.5 deaths per 100,000 children at baseline to 36.0 per 100,000 children in 2008 (rate reduction, 41%; 95% CI, 36 to 47; P<0.001). As compared with baseline, diarrhea-related mortality was 29% lower for children between the ages of 12 and 23 months, few of whom were age-eligible for vaccination. Mortality among unvaccinated children between the ages of 24 and 59 months was not significantly reduced. The reduction in the number of diarrhea-related deaths persisted through two full rotavirus seasons (2008 and 2009).
After the introduction of a rotavirus vaccine, a significant decline in diarrhea-related deaths among Mexican children was observed, suggesting a potential benefit from rotavirus vaccination.
2006 年 2 月至 2007 年 5 月期间,墨西哥分阶段引入单价轮状病毒疫苗。我们评估了 2008 年和 2009 年疫苗接种对墨西哥儿童腹泻死亡的影响。
我们获取了 2003 年 1 月至 2009 年 5 月期间,5 岁以下墨西哥儿童因腹泻导致的死亡数据(无论病因如何)。我们比较了 2008 年和 2008 年及 2009 年轮状病毒流行季的腹泻相关死亡率与基线时(2003-2006 年)的死亡率,此时轮状病毒疫苗尚未引入。疫苗接种覆盖率是根据行政数据估计的。
截至 2007 年 12 月,估计有 74%的 11 个月龄或以下的儿童已接种一剂轮状病毒疫苗。2008 年,5 岁以下儿童腹泻相关死亡人数为 1118 人,比 2003-2006 年期间每年中位数的 1793 人死亡人数减少 675 人。腹泻相关死亡率从基线时的每 10 万名儿童每年 18.1 例降至 2008 年的每 10 万名儿童每年 11.8 例(降低率为 35%;95%置信区间[CI]为 29 至 39;P<0.001)。11 个月龄或以下婴儿的腹泻相关死亡率从基线时的每 10 万名儿童每年 61.5 例降至 2008 年的每 10 万名儿童每年 36.0 例(降低率为 41%;95%CI 为 36 至 47;P<0.001)。与基线相比,12 至 23 个月龄儿童的腹泻相关死亡率降低了 29%,其中很少有符合疫苗接种年龄的儿童。24 至 59 个月龄未接种疫苗儿童的死亡率没有显著降低。腹泻相关死亡人数的减少持续了两个完整的轮状病毒流行季(2008 年和 2009 年)。
在引入轮状病毒疫苗后,观察到墨西哥儿童腹泻相关死亡人数显著下降,表明轮状病毒疫苗接种可能带来益处。